TUNNELPHARMA
DEAD

Serial Number

98250389

Owner

MinakiLabs

Filing Date

Nov 1, 2023

Add to watchlist:

No watchlists yet
View on USPTO

TUNNELPHARMA Trademark

Serial Number: 98250389

TUNNELPHARMA is a trademark filed by MinakiLabs on November 1, 2023. The trademark is classified under Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

MinakiLabs (2 trademarks)

700 Terry Dr.
Joliet, IL 60435

Entity Type: 16

Trademark Details

Filing Date

November 1, 2023

Registration Date

Not Registered

Goods & Services

Software as a service (SAAS) services featuring software for analyzing and reporting self-assessment of illness; Software as a service (SAAS) services featuring software for analyzing and reporting self-assessment of illness for the purpose of ensuring patient safety, tracking infectious disease spread, monitoring mental health conditions, assessing risk of addiction, uncovering pharmaceutical and hospital profiteering practices, and providing therapeutic guidance for mental health improvement. contact tracing; Software as a service (SAAS) services featuring software for identifying persons with possible exposure to drug-related risks, price disparities, pharmaceutical product recalls, malpractices in the healthcare industry, availability of critical medicines, and potential mental health challenges. to facilitate contact tracing; Software as a service (SAAS) services featuring software for monitoring persons with possible exposure to potential drug side effects, risks of addiction, adverse reactions, the effects of essential medications, tracking their mental well-being, and observing industry malpractices. to facilitate contact tracing; Software as a service (SAAS) services featuring software for notifying persons of possible exposure to potential drug interactions, price changes, price gouging activities, updates on vital medications, hospital profiteering practices, and potential mental health risks or triggers. to facilitate contact tracing; Software as a service (SAAS) services featuring software for recording and analyzing real-time location data for predicting the spread of an illness in a community; Software as a service (SAAS) services featuring software for aiding the uninsured in acquiring prescription benefits, offering access to discounted prices for essential and life-saving drugs, lobbying for the provision of mental health drugs, and providing support to individuals with undiagnosed or unaddressed mental health conditions.; Software as a service (SAAS) services featuring software for real-time tracking of essential drug availability, integrating with pharmacy inventory systems, streamlining the drug acquisition process across various categories, offering support for patients in debt due to hospital bills, assisting in restoring credit scores affected by medical debt, and offering therapeutic AI-driven mental health support.; Software as a service (SAAS) services featuring software using artificial intelligence for analyzing and predicting drug price trends, exposing pricing disparities, uncovering industry corruption, tracking hospital profit margins, providing transparency in drug pricing for consumers, assessing the availability of vital medications for critical conditions, evaluating and scoring individuals for potential mental health issues, and analyzing risks of addiction.; Software as a service (SAAS) services, namely, hosting software for use by others for pharmaceutical analytics, exposing pricing disparities, monitoring drug prices for potential price gouging, highlighting profit margins by hospitals and pharmaceutical companies, offering insights into essential and life-saving medications, and aiding in mental health research.; Research and development of computer software; Research, development, design and upgrading of computer software

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Oct 15, 2024 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Oct 15, 2024 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 27, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jun 27, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jun 27, 2024 CNRT
ASSIGNED TO EXAMINER
Jun 12, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 19, 2024 NWOS
NEW APPLICATION ENTERED
Nov 1, 2023 NWAP